An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

AIMS/HYPOTHESIS: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in individuals with type 2 diabetes and hypertension. ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetologia
Autors principals: Hanrahan, John P., Seferovic, Jelena P., Wakefield, James D., Wilson, Phebe J., Chickering, Jennifer G., Jung, Joon, Carlson, Kenneth E., Zimmer, Daniel P., Frelinger, Andrew L., Michelson, Alan D., Morrow, Linda, Hall, Michael, Currie, Mark G., Milne, G. Todd, Profy, Albert T.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054374/
https://ncbi.nlm.nih.gov/pubmed/31858186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-019-05062-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars